List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 355 studies with search of: "Imatinib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Interventions: Drug: imatinib mesylate;   Drug: imatinib;   Drug: imatinib
2 Completed Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia, Myeloid, Chronic
Interventions: Drug: R115777 (Zarnestra);   Drug: Imatinib mesylate (Gleevec)
3 Recruiting STI571 ProspectIve RandomIzed Trial: SPIRIT
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Imatinib mesylate 400 mg;   Drug: Imatinib mesylate 600 mg;   Drug: Imatinib 400 mg + Peg-Interferon;   Drug: Imatinib mesylate 400 mg + Cytarabine
4 Active, not recruiting Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
5 Active, not recruiting Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Imatinib Mesylate
6 Active, not recruiting Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Imatinib Mesylate & Hydroxyurea
7 Active, not recruiting Ph II Imatinib Mesylate + Hydroxyurea in Treatment for Pts w Recurrent/Progressive Meningioma
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Imatinib Mesylate and Hydroxyurea
8 Active, not recruiting Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Cancer
Interventions: Drug: Imatinib Mesylate;   Drug: Docetaxel
9 Not yet recruiting Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
10 Recruiting Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107);   Drug: imatinib (STI571)
11 Active, not recruiting Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Conditions: Solid Tumor;   Thyroid Cancer
Interventions: Drug: Capecitabine (Xeloda);   Drug: DTIC-Dome (Dacarbazine);   Drug: Gleevec (Imatinib Mesylate)
12 Recruiting Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Imatinib Mesylate;   Drug: Pemetrexed
13 Completed Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia;   Chronic Idiopathic Hypereosinophilia
Intervention: Drug: Imatinib
14 Recruiting Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Zactima, Gleevec, Hydroxyurea
15 Not yet recruiting The Study of the Role of Imatinib Mesylate in the Treatment of Colorectal Cancer That Has Spread to the Liver
Conditions: Colorectal Neoplasm;   Colorectal Cancer
Interventions: Drug: Imatinib mesylate followed by imatinib mesylate & panitumumab;   Drug: Standard-of-care treatment with panitumumab
16 Active, not recruiting Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Gleevec, RAD001, and Hydroxyurea
17 Recruiting Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis
Condition: Pulmonary Veno Occlusive Disease
Intervention: Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
18 Recruiting Gleevec Study for Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Imatinib Mesylate
19 Active, not recruiting Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Condition: Uterine Cancer
Interventions: Drug: Imatinib Mesylate;   Drug: Paclitaxel
20 Active, not recruiting Imatinib Mesylate, Busulfan, Fludarabine, and ATG for CML Patients
Condition: Leukemia
Interventions: Drug: Imatinib Mesylate;   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services